Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Betaxolol · 1 trial · 1 indication
babies were monitored and HR/RR monitored and recorded by masked observers, periodically
| Arm | Type | Description |
|---|---|---|
| betaxolol | EXPERIMENTAL | betaxolol 0.25% 2 per day for 3 weeks |
| placebo | PLACEBO_COMPARATOR | masked labeling also 2 per day administration |
| Name | Type | Description |
|---|---|---|
| Betaxolol | DRUG | - |
| topical betaxolol | DRUG | given topically |
Inclusion Criteria: * \<1251 grms birth weight Exclusion Criteria: * ocular defect
Betaxolol is being studied for the development of side effects from betaxolol, specifically in the context of preventing retinopathy of prematurity. It is an investigational small molecule in Phase 1 clinical development.
Betaxolol is being developed by Smith & Nephew SNATS, Inc., which trades under the ticker SNN.
Betaxolol is in Phase 1 clinical development. It is an investigational drug and has not been approved by the FDA.
Betaxolol has one completed clinical trial, NCT01660620, titled 'Topical Betaxolol for the Prevention of Retinopathy of Prematurity'. This Phase 1 trial enrolled 23 participants and was placebo-controlled, randomized, and double-blind.
Betaxolol is the drug name itself. The clinical trial NCT01660620 investigates topical betaxolol for the prevention of retinopathy of prematurity, focusing on the development of side effects from betaxolol.